// App-Quantinova.ai

10090 : Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).

Researchers

Presenter

  • Li Zhang

Principal Investigators

  • Shun Lu

  • Ji Feng Feng

  • Arunee Dechaphunkul

  • Salvatore Chessari

  • Corinna Lanzarotti

  • Karin Jordan

  • Matti S. Aapro

Medical Centers

  • Sun Yat-Sen University Cancer Center, Guangdzhou, Guangdong, China

  • Shanghai Chest Hospital, Jiao Tong University, Shanghai, China

  • China Jinagsu Province Inst of Cancer Rsrch, Jiangsu, China

  • Helsinn Healthcare SA, Pazzallo (Lugano), Switzerland

  • Department of Neurology, University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany

  • Cancer Center, Clinique de Genolier, Genolier, Switzerland

Locations

  • Thailand

  • China

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • NDC80 Kinetochore Complex Component

Drug/Treatment

  • Netupitant/Palonosetron

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Palonosetron

  • Aprepitant

  • Netupitant

  • Cisplatin

  • NEPA

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Non Inferiority

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved